Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters











Publication year range
1.
Sci Rep ; 11(1): 4106, 2021 02 18.
Article in English | MEDLINE | ID: mdl-33602992

ABSTRACT

In chronic obstructive pulmonary disease (COPD) apoptotic bronchial epithelial cells are increased, and their phagocytosis by alveolar macrophages (AM) is decreased alongside bacterial phagocytosis. Epithelial cellular lipids, including those exposed on uncleared apoptotic bodies, can become oxidized, and may be recognized and presented as non-self by antigen presenting cells. CD1b is a lipid-presenting protein, previously only described in dendritic cells. We investigated whether CD1b is upregulated in COPD AM, and whether lipid oxidation products are found in the airways of cigarette smoke (CS) exposed mice. We also characterise CD1b for the first time in a range of macrophages and assess CD1b expression and phagocytic function in response to oxidised lipid. Bronchoalveolar lavage and exhaled breath condensate were collected from never-smoker, current-smoker, and COPD patients and AM CD1b expression and airway 8-isoprostane levels assessed. Malondialdehyde was measured in CS-exposed mouse airways by confocal/immunofluorescence. Oxidation of lipids produced from CS-exposed 16HBE14o- (HBE) bronchial epithelial cells was assessed by spectrophotometry and changes in lipid classes assessed by mass spectrometry. 16HBE cell toxicity was measured by flow cytometry as was phagocytosis, CD1b expression, HLA class I/II, and mannose receptor (MR) in monocyte derived macrophages (MDM). AM CD1b was significantly increased in COPD smokers (4.5 fold), COPD ex-smokers (4.3 fold), and smokers (3.9 fold), and AM CD1b significantly correlated with disease severity (FEV1) and smoking pack years. Airway 8-isoprostane also increased in smokers and COPD smokers and ex-smokers. Malondialdehyde was significantly increased in the bronchial epithelium of CS-exposed mice (MFI of 18.18 vs 23.50 for control). Oxidised lipid was produced from CS-exposed bronchial epithelial cells (9.8-fold of control) and showed a different overall lipid makeup to that of control total cellular lipid. This oxidised epithelial lipid significantly upregulated MDM CD1b, caused bronchial epithelial cell toxicity, and reduced MDM phagocytic capacity and MR in a dose dependent manner. Increased levels of oxidised lipids in the airways of COPD patients may be responsible for reduced phagocytosis and may become a self-antigen to be presented by CD1b on macrophages to perpetuate disease progression despite smoking cessation.


Subject(s)
Antigens, CD1/immunology , Lipid Metabolism , Macrophages, Alveolar/immunology , Pulmonary Disease, Chronic Obstructive/metabolism , Adult , Aged , Aged, 80 and over , Animals , Bronchoalveolar Lavage Fluid/cytology , Female , Flow Cytometry , Forced Expiratory Volume , Gas Chromatography-Mass Spectrometry , Humans , Male , Malondialdehyde/metabolism , Mass Spectrometry , Mice , Microscopy, Fluorescence , Middle Aged , Oxidation-Reduction , Pulmonary Disease, Chronic Obstructive/immunology , Smoking/adverse effects , Tobacco Smoke Pollution/adverse effects , Vital Capacity , Young Adult
2.
Respirology ; 26(3): 241-248, 2021 03.
Article in English | MEDLINE | ID: mdl-33045125

ABSTRACT

BACKGROUND AND OBJECTIVE: Long-term data on children with PBB has been identified as a research priority. We describe the 5-year outcomes for children with PBB to ascertain the presence of chronic respiratory disease (bronchiectasis, recurrent PBB and asthma) and identify the risk factors for these. METHODS: Prospective cohort study was undertaken at the Queensland Children's Hospital, Brisbane, Australia, of 166 children with PBB and 28 controls (undergoing bronchoscopy for symptoms other than chronic wet cough). Monitoring was by monthly contact via research staff. Clinical review, spirometry and CT chest were performed as clinically indicated. RESULTS: A total of 194 children were included in the analysis. Median duration of follow-up was 59 months (IQR: 50-71 months) post-index PBB episode, 67.5% had ongoing symptoms and 9.6% had bronchiectasis. Significant predictors of bronchiectasis were recurrent PBB in year 1 of follow-up (ORadj = 9.6, 95% CI: 1.8-50.1) and the presence of Haemophilus influenzae in the BAL (ORadj = 5.1, 95% CI: 1.4-19.1). Clinician-diagnosed asthma at final follow-up was present in 27.1% of children with PBB. A significant BDR (FEV1 improvement >12%) was obtained in 63.5% of the children who underwent reversibility testing. Positive allergen-specific IgE (ORadj = 14.8, 95% CI: 2.2-100.8) at baseline and bronchomalacia (ORadj = 5.9, 95% CI: 1.2-29.7) were significant predictors of asthma diagnosis. Spirometry parameters were in the normal range. CONCLUSION: As a significant proportion of children with PBB have ongoing symptoms at 5 years, and outcomes include bronchiectasis and asthma, they should be carefully followed up clinically. Defining biomarkers, endotypes and mechanistic studies elucidating the different outcomes are now required.


Subject(s)
Bacterial Infections , Bronchiectasis , Bronchitis, Chronic , Bronchitis , Cough/physiopathology , Bronchiectasis/epidemiology , Bronchitis/diagnosis , Bronchitis/epidemiology , Child , Humans , Prospective Studies
3.
PLoS One ; 10(6): e0129522, 2015.
Article in English | MEDLINE | ID: mdl-26070210

ABSTRACT

Coccidioides spp. are dimorphic pathogenic fungi whose parasitic forms cause coccidioidomycosis (Valley fever) in mammalian hosts. We use an innovative interdisciplinary approach to analyze one-on-one encounters between human neutrophils and two forms of Coccidioides posadasii. To examine the mechanisms by which the innate immune system coordinates different stages of the host response to fungal pathogens, we dissect the immune-cell response into chemotaxis, adhesion, and phagocytosis. Our single-cell technique reveals a surprisingly strong response by initially quiescent neutrophils to close encounters with C. posadasii, both from a distance (by complement-mediated chemotaxis) as well as upon contact (by serum-dependent adhesion and phagocytosis). This response closely resembles neutrophil interactions with Candida albicans and zymosan particles, and is significantly stronger than the neutrophil responses to Cryptococcus neoformans, Aspergillus fumigatus, and Rhizopus oryzae under identical conditions. The vigorous in vitro neutrophil response suggests that C. posadasii evades in vivo recognition by neutrophils through suppression of long-range mobilization and recruitment of the immune cells. This observation elucidates an important paradigm of the recognition of microbes, i.e., that intact immunotaxis comprises an intricate spatiotemporal hierarchy of distinct chemotactic processes. Moreover, in contrast to earlier reports, human neutrophils exhibit vigorous chemotaxis toward, and frustrated phagocytosis of, the large spherules of C. posadasii under physiological-like conditions. Finally, neutrophils from healthy donors and patients with chronic coccidioidomycosis display subtle differences in their responses to antibody-coated beads, even though the patient cells appear to interact normally with C. posadasii endospores.


Subject(s)
Chemotaxis , Coccidioides/physiology , Neutrophils/cytology , Neutrophils/microbiology , Phagocytosis , Spores, Fungal/physiology , Antifungal Agents/pharmacology , Cell Adhesion/drug effects , Chemotaxis/drug effects , Coccidioides/drug effects , Coccidioidomycosis/microbiology , Complement System Proteins/immunology , Humans , Immunity, Innate/drug effects , Neutrophils/drug effects , Phagocytosis/drug effects , Spores, Fungal/drug effects , Time Factors , Tissue Donors
4.
J Virol ; 86(4): 2239-50, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22156519

ABSTRACT

The Step Trial showed that the MRKAd5 HIV-1 subtype B Gag/Pol/Nef vaccine did not protect men from HIV infection or reduce setpoint plasma viral RNA (vRNA) levels but, unexpectedly, it did modestly enhance susceptibility to HIV infection in adenovirus type 5 (Ad5)-seropositive, uncircumcised men. As part of the process to understand the results of the Step Trial, we designed a study to determine whether rhesus macaques chronically infected with a host-range mutant Ad5 (Ad5hr) and then immunized with a replication defective Ad5 SIVmac239 Gag/Pol/Nef vaccine were more resistant or susceptible to SIV infection than unimmunized rhesus macaques challenged with a series of escalating dose penile exposures to SIVmac 251. The Ad5 SIV vaccine induced CD8(+) T cell responses in 70% of the monkeys, which is similar to the proportion of humans that responded to the vaccine in the Step Trial. However, the vaccine did not protect vaccinated animals from penile SIV challenge. At the lowest SIV exposure dose (10(3) 50% tissue culture infective doses), 2 of 9 Ad5-seropositive animals immunized with the Ad5 SIV vaccine became infected compared to 0 of 34 animals infected in the other animal groups (naive animals, Ad5-seropositive animals immunized with the empty Ad5 vector, Ad5-seronegative animals immunized with the Ad5 SIV vaccine, and Ad5-seronegative animals immunized with the empty Ad5 vector). Penile exposure to more concentrated virus inocula produced similar rates of infection in all animal groups. Although setpoint viral loads were unaffected in Step vaccinees, the Ad5 SIV-immunized animals had significantly lower acute-phase plasma vRNA levels compared to unimmunized animals. Thus, the results of the nonhuman primate (NHP) study described here recapitulate the lack of protection against HIV acquisition seen in the Step Trial and suggest a greater risk of infection in the Ad5-seropositive animals immunized with the Ad5 SIV vaccine. Further studies are necessary to confirm the enhancement of virus acquisition and to discern associated mechanisms.


Subject(s)
AIDS Vaccines/immunology , Gene Products, env/immunology , Gene Products, gag/immunology , Gene Products, nef/immunology , HIV Infections/prevention & control , SAIDS Vaccines/immunology , Simian Acquired Immunodeficiency Syndrome/prevention & control , Simian Immunodeficiency Virus/immunology , AIDS Vaccines/administration & dosage , AIDS Vaccines/genetics , Adenoviruses, Human/genetics , Adenoviruses, Human/physiology , Animals , Antibodies, Viral/immunology , Defective Viruses/genetics , Defective Viruses/physiology , Disease Models, Animal , Gene Products, env/administration & dosage , Gene Products, env/genetics , Gene Products, gag/administration & dosage , Gene Products, gag/genetics , Gene Products, nef/administration & dosage , Gene Products, nef/genetics , Genetic Vectors/genetics , Genetic Vectors/metabolism , HIV/genetics , HIV/immunology , HIV Infections/immunology , HIV Infections/virology , HIV-1/genetics , HIV-1/immunology , Humans , Immunization , Macaca mulatta , Male , SAIDS Vaccines/administration & dosage , SAIDS Vaccines/genetics , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Acquired Immunodeficiency Syndrome/virology , Simian Immunodeficiency Virus/genetics
5.
J Virol ; 85(1): 348-56, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20980517

ABSTRACT

Measles remains a leading cause of death worldwide among children because it suppresses immune function. The measles virus (MV) P gene encodes three proteins (P, V, and C) that interfere with innate immunity, controlling STAT1, STAT2, mda5, and perhaps other key regulators of immune function. We identified here three residues in the shared domain of the P and V proteins-tyrosine 110, valine 112, and histidine 115-that function to retain STAT1 in the cytoplasm and inhibit interferon transcription. This information was used to generate a recombinant measles virus unable to antagonize STAT1 function (STAT1-blind MV) differing only in these three residues from a wild-type strain of well-defined virulence. This virus was used to assess the relevance of P and V interactions with STAT1 for virulence in primates. When a group of six rhesus monkeys (Macaca mulatta) was inoculated intranasally with STAT1-blind MV, viremia was short-lived, and the skin rash and other clinical signs observed with wild-type MV were absent. The STAT1-blind virus less efficiently controlled the inflammatory response, as measured by enhanced transcription of interleukin-6 and tumor necrosis factor alpha in peripheral blood mononuclear cells from infected hosts. Importantly, neutralizing antibody titers and MV-specific T-cell responses were equivalent in hosts infected with either virus. These findings indicate that efficient MV interactions with STAT1 are required to sustain virulence in a natural host by controlling the inflammatory response against the virus. They also suggest that selectively STAT1-blind MV may have utility as vectors for targeted oncolysis and vaccination.


Subject(s)
Inflammation/prevention & control , Measles virus/pathogenicity , Phosphoproteins/genetics , Recombination, Genetic , STAT1 Transcription Factor/antagonists & inhibitors , Viral Proteins/genetics , Amino Acid Sequence , Animals , Chlorocebus aethiops , HeLa Cells , Humans , Inflammation/immunology , Macaca mulatta , Measles/immunology , Measles/prevention & control , Measles/virology , Measles Vaccine/genetics , Measles Vaccine/immunology , Measles virus/genetics , Molecular Sequence Data , Mutation , Phosphoproteins/chemistry , Phosphoproteins/metabolism , STAT1 Transcription Factor/genetics , STAT1 Transcription Factor/metabolism , Vero Cells , Viral Proteins/chemistry , Viral Proteins/metabolism , Virulence
6.
J Virol ; 84(7): 3413-20, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20071568

ABSTRACT

The signaling lymphocytic activation molecule (SLAM; CD150) is the immune cell receptor for measles virus (MV). To assess the importance of the SLAM-MV interactions for virus spread and pathogenesis, we generated a wild-type IC-B MV selectively unable to recognize human SLAM (SLAM-blind). This virus differs from the fully virulent wild-type IC-B strain by a single arginine-to-alanine substitution at amino acid 533 of the attachment protein hemagglutinin and infects cells through SLAM about 40 times less efficiently than the isogenic wild-type strain. Ex vivo, this virus infects primary lymphocytes at low levels regardless of SLAM expression. When a group of six rhesus monkeys (Macaca mulatta) was inoculated intranasally with the SLAM-blind virus, no clinical symptoms were documented. Only one monkey had low-level viremia early after infection, whereas all the hosts in the control group had high viremia levels. Despite minimal, if any, viremia, all six hosts generated neutralizing antibody titers close to those of the control monkeys while MV-directed cellular immunity reached levels at least as high as in wild-type-infected monkeys. These findings prove formally that efficient SLAM recognition is necessary for MV virulence and pathogenesis. They also suggest that the selectively SLAM-blind wild-type MV can be developed into a vaccine vector.


Subject(s)
Adaptive Immunity , Antigens, CD/physiology , Measles virus/physiology , Receptors, Cell Surface/physiology , Animals , Cell Line , Humans , Macaca mulatta , Measles Vaccine/immunology , Measles virus/immunology , Measles virus/pathogenicity , Membrane Cofactor Protein/physiology , Signaling Lymphocytic Activation Molecule Family Member 1 , T-Lymphocytes/virology , Viral Proteins/physiology , Virus Internalization
7.
J Virol ; 83(17): 9013-7, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19535451

ABSTRACT

The widely used hepatitis B virus (HBV) vaccine is based on three doses of hepatitis B surface antigen (HBsAg) protein. We previously showed that vectored measles viruses (MV) expressing HBsAg retain measles vaccine function in monkeys but do not induce a protective anti-HBs response in all animals. We show here that a single dose of HBsAg protein following a three-dose vaccination regimen with an optimized HBsAg-expressing MV elicits protective anti-HBs responses in all four vaccinated Rhesus monkeys. Vaccination strategies coupling the effective, long-term immunity elicited by the high-coverage MV vaccine to prophylactic HBV immunity are discussed.


Subject(s)
Genetic Vectors , Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/immunology , Hepatitis B/prevention & control , Immunization/methods , Measles virus/genetics , Animals , Hepatitis B Antibodies/blood , Hepatitis B Surface Antigens/genetics , Hepatitis B Vaccines/genetics , Humans , Interferon-gamma/metabolism , Leukocytes, Mononuclear/immunology , Macaca mulatta , Neutralization Tests , Vaccines, Subunit/genetics , Vaccines, Subunit/immunology , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Viremia/prevention & control
8.
J Clin Invest ; 118(7): 2448-58, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18568079

ABSTRACT

The current model of measles virus (MV) pathogenesis implies that apical infection of airway epithelial cells precedes systemic spread. An alternative model suggests that primarily infected lymphatic cells carry MV to the basolateral surface of epithelial cells, supporting MV shedding into the airway lumen and contagion. This model predicts that a mutant MV, unable to enter cells through the unidentified epithelial cell receptor (EpR), would remain virulent but not be shed. To test this model, we identified residues of the MV attachment protein sustaining EpR-mediated cell fusion. These nonpolar or uncharged polar residues defined an area located near the binding site of the signaling lymphocytic activation molecule (SLAM), the receptor for MV on lymphatic cells. We then generated an EpR-blind virus maintaining SLAM-dependent cell entry and inoculated rhesus monkeys intranasally. Hosts infected with the selectively EpR-blind MV developed rash and anorexia while averaging slightly lower viremia than hosts infected with wild-type MV but did not shed virus in the airways. The mechanism restricting shedding was characterized using primary well-differentiated human airway epithelial cells. Wild-type MV infected columnar epithelial cells bearing tight junctions only when applied basolaterally, while the EpR-blind virus did not infect these cells. Thus, EpR is probably a basolateral protein, and infection of the airway epithelium is not essential for systemic spread and virulence of MV.


Subject(s)
Measles virus/pathogenicity , Measles/metabolism , Receptors, Virus/metabolism , Viral Proteins/metabolism , Virus Shedding/physiology , Amino Acid Sequence , Animals , Antibody Formation/immunology , Antigens, CD/metabolism , Cell Line, Transformed , Cell Line, Tumor , Epithelial Cells/metabolism , Epithelial Cells/virology , Female , Haplorhini , Humans , Leukocytes, Mononuclear/virology , Macaca mulatta , Male , Measles/transmission , Measles/virology , Measles virus/metabolism , Models, Molecular , Molecular Sequence Data , Mutation , Receptors, Cell Surface/metabolism , Respiratory Mucosa/virology , Signaling Lymphocytic Activation Molecule Family Member 1 , Viral Proteins/chemistry , Viral Proteins/genetics , Virulence , Virus Attachment
9.
J Virol ; 82(11): 5359-67, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18385234

ABSTRACT

Patients recruited in virus-based cancer clinical trials and immunocompromised individuals in need of vaccination would profit from viral strains with defined attenuation mechanisms. We generated measles virus (MV) strains defective for the expression of either the V protein, a modulator of the innate immune response, or the C protein, which has multiple functions. The virulence of these strains was compared with that of the parental wild-type MV in a natural host, Macaca mulatta. Skin rash, viremia, and the strength of the innate and adaptive immune responses were characterized in groups of six animals. Replication of V- or C-protein-defective viruses was short-lived and reached lower levels in peripheral blood mononuclear cells and lymphatic organs compared to the wild-type virus; none of the mutants reverted to the wild type. The neutralizing antibody titers and MV-specific T-cell responses were equivalent in monkeys infected with the viral strains tested, documenting strong adaptive immune responses. In contrast, the inflammatory response was better controlled by wild-type MV, as revealed by inhibition of interleukin-6 and tumor necrosis factor alpha transcription. The interferon response was also better controlled by the wild-type virus than by the defective viruses. Since V- and C-defective MVs induce strong adaptive immune responses while spreading less efficiently, they may be developed as vaccines for immunocompromised individuals. Moreover, MV unable to interact with single innate immunity proteins may be developed for preferential replication in tumors with specific contexts of vulnerability.


Subject(s)
Infection Control , Interferons/biosynthesis , Macaca mulatta/immunology , Measles virus/immunology , Measles virus/metabolism , Viral Proteins/immunology , Viral Proteins/metabolism , Adaptation, Physiological/immunology , Amino Acid Sequence , Animals , Base Sequence , Cell Line , Chlorocebus aethiops , Humans , Inflammation/prevention & control , Interferons/genetics , Measles/genetics , Measles/immunology , Measles/metabolism , Measles/transmission , Measles virus/chemistry , Measles virus/genetics , Molecular Sequence Data , Mutation/genetics , Th1 Cells/immunology , Th2 Cells/immunology , Viral Proteins/chemistry , Viral Proteins/genetics , Virus Replication
10.
Virology ; 373(1): 39-50, 2008 Mar 30.
Article in English | MEDLINE | ID: mdl-18155263

ABSTRACT

To identify genetic changes that lead to the attenuation of measles virus (MV), a strain of MV that is pathogenic in rhesus macaques was adapted to grow in Vero cells, Vero/hSLAM cells and, to simulate the process used to derive live attenuated vaccines, in primary chicken embryo fibroblasts (CEF). Comparison of the complete genomic sequences of the pathogenic wild-type (Davis87-wt) and four cell culture-adapted strains derived from it showed complete conservation of sequence in the Vero/hSLAM-passaged virus. Viruses adapted to Vero cells and CEF had predicted amino acid changes in the nucleocapsid protein, phosphoprotein, V protein, C protein, matrix protein, and the cytoplasmic tail of the hemagglutinin protein. All four cell culture-adapted strains, including the Vero/hSLAM cell-passaged virus, were able to productively infect Vero cells, but the peak viral titers differed. The Vero cell-adapted strains were unable to replicate in Chinese Hamster Ovary cells expressing CD46, indicating that they had not adapted to use the CD46 receptor. The Vero/hSLAM cell-passaged virus retained pathogenicity in rhesus macaques as measured by the appearance of a skin rash while the Vero cell-adapted and CEF-adapted strains had lost the ability to cause a rash. There were no significant differences in viral titers in peripheral blood mononuclear cells among monkeys infected with any of the viral stocks tested. These results identify a limited number of genetic changes in the genome of MV that lead to attenuation in vivo.


Subject(s)
Amino Acid Substitution , Disease Models, Animal , Measles virus/genetics , Measles virus/pathogenicity , Measles/physiopathology , Adaptation, Physiological , Animals , Antigens, CD/metabolism , CHO Cells/virology , Chick Embryo , Chlorocebus aethiops , Cricetinae , Cricetulus , Female , Humans , Macaca mulatta , Male , Measles/virology , Measles virus/physiology , Receptors, Cell Surface/metabolism , Signaling Lymphocytic Activation Molecule Family Member 1 , Vero Cells/virology , Virulence , Virus Replication
11.
J Virol ; 81(19): 10597-605, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17634218

ABSTRACT

Hepatitis B virus (HBV) acute and chronic infections remain a major worldwide health problem. Towards developing an anti-HBV vaccine with single-dose scheme potential, we engineered infectious measles virus (MV) genomic cDNAs with a vaccine strain background and expression vector properties. Hepatitis B surface antigen (HBsAg) expression cassettes were inserted into this cDNA and three MVs expressing HBsAg at different levels generated. All vectored MVs, which secrete HBsAg as subviral particles, elicited humoral responses in MV-susceptible genetically modified mice. However, small differences in HBsAg expression elicited vastly different HBsAg antibody levels. The two vectors inducing the highest HBsAg antibody levels were inoculated into rhesus monkeys (Macaca mulatta). After challenge with a pathogenic MV strain (Davis87), control naive monkeys showed a classic measles rash and high viral loads. In contrast, all monkeys immunized with vaccine or a control nonvectored recombinant vaccine or HBsAg-expressing vectored MV remained healthy, with low or undetectable viral loads. After a single vaccine dose, only the vector expressing HBsAg at the highest levels elicited protective levels of HBsAg antibodies in two of four animals. These observations reveal an expression threshold for efficient induction of HBsAg humoral immune responses. This threshold is lower in mice than in macaques. Implications for the development of divalent vaccines based on live attenuated viruses are discussed.


Subject(s)
Hepatitis B Antibodies/immunology , Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/immunology , Hepatitis B/prevention & control , Measles virus/genetics , Measles/prevention & control , Animals , Antibody Formation , Base Sequence , Genetic Vectors/genetics , Genetic Vectors/immunology , Hepatitis B Antibodies/blood , Hepatitis B Surface Antigens/genetics , Hepatitis B Vaccines/genetics , Macaca mulatta , Measles virus/immunology , Mice , Mice, Transgenic , Molecular Sequence Data
12.
Virology ; 350(2): 429-32, 2006 Jul 05.
Article in English | MEDLINE | ID: mdl-16569419

ABSTRACT

Maternal antibody prevents the use of live, attenuated measles vaccine (LAV) before 6-9 months of age, but vaccinated 6-month-old infants can mount a T cell response. An infant macaque model was used to study the immune response to LAV in the newborn in the presence or absence of maternal antibody. Four newborn monkeys without detectable maternal antibody and 9 newborns with passive measles antibody were vaccinated with LAV. Only the infants without passive antibody seroconverted after vaccination and 3 of 4 of these infants also developed measles-specific interferon gamma+ T cells. The monkeys were challenged with wild-type measles virus at 5 months of age, and 7 of 9 infants vaccinated in the presence of passive antibody had systemic infection and skin rash, while 3 of the 4 infants vaccinated in the absence of passive antibody were protected from viremia and rash. This suggests that the newborn can respond to LAV but that maternal antibody suppresses the priming of both humoral and cellular immunity at birth.


Subject(s)
Antibody Formation , Immunity, Cellular , Maternal-Fetal Exchange/immunology , Measles Vaccine/immunology , Female , Humans , Infant, Newborn , Pregnancy , Vaccination
SELECTION OF CITATIONS
SEARCH DETAIL